Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Dredge

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Cancer Research|December 6, 2014
The increasing urgency for standards in basic biologic research published recently in cancer research--letterKeith Dredge
Current Opinion in Investigational Drugs (London, England : 2000)|May 26, 2005
CC-1088 CelgeneKeith Dredge
Current Opinion in Investigational Drugs (London, England : 2000)|July 10, 2004
AE-941 (AEterna)Keith Dredge
Advances in Experimental Medicine and Biology|April 11, 2020
Heparanase Inhibition by Pixatimod (PG545): Basic Aspects and Future PerspectivesEdward Hammond, Keith Dredge
Plos One|January 10, 2013
PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma modelEdward Hammond, Ralf Brandt, Keith Dredge
Reviews on Recent Clinical Trials|May 14, 2008
Dendritic cell immunotherapy for melanomaJudy C Peng, Ranjeny Thomas, Keith Dredge
Nature Reviews. Cancer|April 2, 2004
The evolution of thalidomide and its IMiD derivatives as anticancer agentsJ Blake Bartlett, Keith Dredge, Angus G Dalgleish
FEBS Open Bio|November 20, 2013
Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analoguesEdward Hammond, Paul Handley, Keith Dredge, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|August 7, 2003
Angiogenesis inhibitors in cancer therapyKeith Dredge, Angus G Dalgleish, J Blake Marriott
Expert Opinion on Biological Therapy|January 9, 2003
Recent developments in antiangiogenic therapyKeith Dredge, Angus G Dalgleish, J Blake Marriott
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Cancer Research|December 6, 2014
The increasing urgency for standards in basic biologic research published recently in cancer research--letterKeith Dredge
Current Opinion in Investigational Drugs (London, England : 2000)|May 26, 2005
CC-1088 CelgeneKeith Dredge
Current Opinion in Investigational Drugs (London, England : 2000)|July 10, 2004
AE-941 (AEterna)Keith Dredge
Advances in Experimental Medicine and Biology|April 11, 2020
Heparanase Inhibition by Pixatimod (PG545): Basic Aspects and Future PerspectivesEdward Hammond, Keith Dredge
Plos One|January 10, 2013
PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma modelEdward Hammond, Ralf Brandt, Keith Dredge
Reviews on Recent Clinical Trials|May 14, 2008
Dendritic cell immunotherapy for melanomaJudy C Peng, Ranjeny Thomas, Keith Dredge
Nature Reviews. Cancer|April 2, 2004
The evolution of thalidomide and its IMiD derivatives as anticancer agentsJ Blake Bartlett, Keith Dredge, Angus G Dalgleish
FEBS Open Bio|November 20, 2013
Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analoguesEdward Hammond, Paul Handley, Keith Dredge, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|August 7, 2003
Angiogenesis inhibitors in cancer therapyKeith Dredge, Angus G Dalgleish, J Blake Marriott
Expert Opinion on Biological Therapy|January 9, 2003
Recent developments in antiangiogenic therapyKeith Dredge, Angus G Dalgleish, J Blake Marriott
Pageof 4